CPH Pharma ApS Financials, key figures and credit report
Gross profit 4 432.2 kDKK FY 2025 +32.2% vs 2024
EBIT 2 451.5 kDKK FY 2025 +48.2% vs 2024
Net debt -2 133.7 kDKK FY 2025 +37.6% vs 2024
Quick ratio 3.8 FY 2025 -0.7 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 1 577.56 | 1 747.39 | 3 017.00 | 3 353.61 | 4 432.16 |
| Employee benefit expenses | - 423.52 | - 986.98 | -1 692.01 | -1 699.22 | -1 980.65 |
| EBIT | 1 154.05 | 760.42 | 1 324.99 | 1 654.39 | 2 451.51 |
| Other financial income | 1.19 | 0.07 | |||
| Other financial expenses | -6.60 | -8.30 | -0.11 | -0.83 | -4.20 |
| Pre-tax profit | 1 147.45 | 752.12 | 1 326.07 | 1 653.63 | 2 447.32 |
| Income taxes | - 252.45 | - 165.59 | - 291.74 | - 396.49 | - 565.47 |
| Net earnings | 895.00 | 586.52 | 1 034.32 | 1 257.14 | 1 881.85 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 366.40 | 227.70 | 845.78 | 547.86 | 1 894.59 |
| Current amounts owed by group member comp. | 188.22 | ||||
| Current other receivables | 145.65 | 77.21 | |||
| Short term receivables total | 512.06 | 227.70 | 845.78 | 736.08 | 1 971.80 |
| Cash and bank deposits | 1 128.44 | 1 665.34 | 2 037.71 | 3 422.06 | 2 244.96 |
| Cash and cash equivalents | 1 128.44 | 1 665.34 | 2 037.71 | 3 422.06 | 2 244.96 |
| Balance sheet total (assets) | 1 640.50 | 1 893.04 | 2 883.49 | 4 158.14 | 4 216.76 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 |
| Shares repurchased | 350.00 | 350.00 | 2 000.00 | 2 000.00 | 1 800.00 |
| Retained earnings | - 252.54 | 292.46 | -1 121.02 | -86.69 | - 629.55 |
| Profit of the financial year | 895.00 | 586.52 | 1 034.32 | 1 257.14 | 1 881.85 |
| Shareholders equity total | 1 042.46 | 1 278.98 | 1 963.31 | 3 220.45 | 3 102.30 |
| Non-current liabilities total | |||||
| Current trade creditors | 323.81 | 0.90 | |||
| Current owed to group member | 138.77 | 195.81 | 227.24 | 111.26 | |
| Short-term deferred tax liabilities | 252.45 | 165.59 | 291.74 | 396.49 | 434.47 |
| Other non-interest bearing current liabilities | 206.82 | 252.65 | 401.20 | 217.39 | 567.83 |
| Current liabilities total | 598.04 | 614.06 | 920.18 | 937.69 | 1 114.46 |
| Balance sheet total (liabilities) | 1 640.50 | 1 893.04 | 2 883.49 | 4 158.14 | 4 216.76 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated